Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37004598)

  • 21. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
    J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term survival and toxicity in patients with neuroendocrine tumors treated with
    Kennedy KR; Turner JH; MacDonald WBG; Claringbold PG; Boardman G; Ransom DT
    Cancer; 2022 Jun; 128(11):2182-2192. PubMed ID: 35363879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with
    Alipour R; Jackson P; Bressel M; Hogg A; Callahan J; Hicks RJ; Kong G
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2997-3010. PubMed ID: 37184682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Efficacy, Survival, and Safety of [
    Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
    Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.
    Severi S; Nanni O; Bodei L; Sansovini M; Ianniello A; Nicoletti S; Scarpi E; Matteucci F; Gilardi L; Paganelli G
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):881-8. PubMed ID: 23443937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
    Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
    Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
    [No Abstract]   [Full Text] [Related]  

  • 27. Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours.
    Almeamar H; Cullen L; Murphy DJ; Crowley RK; Toumpanakis C; Welin S; O'Shea D; O'Toole D
    J Neuroendocrinol; 2022 Jun; 34(6):e13138. PubMed ID: 35485450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience.
    Vukomanovic V; Nedic KV; Radojevic MZ; Dagovic A; Milosavljevic N; Markovic M; Ignjatovic V; Simic Vukomanovic I; Djukic S; Sreckovic M; Backovic M; Vuleta M; Djukic A; Vukicevic V; Ignjatovic V
    Front Endocrinol (Lausanne); 2023; 14():1270421. PubMed ID: 38317712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study.
    Paganelli G; Sansovini M; Ambrosetti A; Severi S; Monti M; Scarpi E; Donati C; Ianniello A; Matteucci F; Amadori D
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1845-51. PubMed ID: 24615468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
    Kesavan M; Turner JH
    Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of
    Shah RG; Merlin MA; Adant S; Zine-Eddine F; Beauregard JM; Shah GM
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with
    Minczeles NS; de Herder WW; Feelders RA; Verburg FA; Hofland J; Brabander T
    J Nucl Med; 2023 Jan; 64(1):40-46. PubMed ID: 35680417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
    Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
    Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES
    Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival predictors of
    Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors.
    Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R
    Clin Nucl Med; 2020 Sep; 45(9):e393-e399. PubMed ID: 32604121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
    Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.